Table IV.
Groups | Before treatment | After treatment | t-test | P-value |
---|---|---|---|---|
Rituximab group (n=79) | 12.3±1.7 | 75.3±8.4 | 65.34 | <0.001 |
Cyclophosphamide group (n=86) | 12.6±1.3 | 62.3±7.0a | 64.74 | <0.001 |
Combined therapy group (n=84) | 12.5±1.4 | 92.3±9.8a,b | 73.88 | <0.001 |
F-value | 0.882 | 267.9 | ||
P-value | 0.415 | <0.001 |
P<0.05, compared with rituximab group
P<0.05, compared with cyclophosphamide group.